Yonhap Infomax NewsSouth Korean biotech firm Alteogen secures exclusive license deal with Biogen for subcutaneous formulation technology, potentially worth up to $549 million in milestones plus royalties, with $20 million upfront payment for developing two biopharmaceutical products using ALT-B4 platform and HybrozymeTM technology.
#YonhapInfomax #Alteogen #Biogen #SubcutaneousFormulation #LicenseAgreement #ALTB4 #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=112015
#YonhapInfomax #Alteogen #Biogen #SubcutaneousFormulation #LicenseAgreement #ALTB4 #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=112015
Alteogen Signs Subcutaneous Formulation Technology Deal with Biogen Worth Up to 870 Billion Won
South Korean biotech firm Alteogen secures exclusive license deal with Biogen for subcutaneous formulation technology, potentially worth up to $549 million in milestones plus royalties, with $20 million upfront payment for developing two biopharmaceutical products using ALT-B4 platform and HybrozymeTM technology.